Cardiff Oncology Inc - Company Profile
Powered by 
All the sales intelligence you need on Cardiff Oncology Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Cardiff Oncology Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Cardiff Oncology Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
Cardiff Oncology Inc (Cardiff) is focused on developing novel therapies through the inhibition of Polo-like kinase 1 (PLK1), a validated target in oncology.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
The company’s R&D is focused on the development of its lead drug candidate, onvansertib, which is in the early stages of clinical development. The company is conducting multiple clinical trials across various cancer indications, including RAS-mutated metastatic colorectal cancer (mCRC), pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple-negative breast cancer (TNBC). The company is exploring the efficacy of onvansertib in combination with standard-of-care cancer agents and is utilizing biomarker analyses to optimize drug development and patient care. The company has an in-house research and development laboratory in San Diego, California. This unit is responsible for optimizing drug development and patient care, conducting correlative biomarker analyses, and supporting the clinical development of onvansertib. It has 57 issued patents and 57 pending patent applications in the U.S. and abroad. In FY2024, the company invested US$36.8 million in its R&D activities, which increased 12.1% YoY.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer